ALTEOGEN Inc. (196170.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩218,500 (+0.00%) as of
Key statistics
- Market cap
- 15.19T
- Forward P/E
- 40.44
- Dividend yield
- 0.13%
- 52-week range
- 194,615.39 – 437,692.31
- Beta
- 0.98
- Revenue (TTM)
- 254.01B
- Profit margin
- 75.47%
- Analyst target
- ₩405,512.8
- Volume
- 232.50k
About ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Daejeon, South Korea
- Employees
- 181
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.